Sulopenem fails to meet primary endpoint in Phase III trial

In the SURE 2 clinical trial (n=1395), this thiopenem broad spectrum antibiotic failed to achieve statistical non-inferiority vs ertapenem for the treatment of complicated urinary tract infection (responder rates of 67.8% vs 73.9% respectively).

PharmaTimes